Search Results
A New NCCN Guideline: Venous Thromboembolic Disease
Christopher E. Desch
HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients
Priyanka Reddy, James Martin, and Alberto Montero
.01). Patients with liver metastases prior to starting CDKI were less likely to be alive at 60 months compared to patients without liver metastases (26.1% vs. 59.8%, p=0.0008). Similarly, 48-month PFS was significantly lower in patients with liver metastases vs
Interventional Oncology: Adding Options to the Care of Patients with Cancer
Daniel B. Brown
's clinical course also provides relevant insights into the current status of interventional oncology, particularly as it relates to treatment options for liver metastases from CRC. Minimally invasive image-guided treatments, such as chemoembolization
CLO20-056: Real-Life Experience of Treatment With Anti-Programmed Cell Death-1 (PD-1) or Programmed Death-Ligand 1 (PD-L1) Antibodies in Patients With Non-Small Cells Lung Cancer (NSCLC)
Gianfranco Puppo, Gian Paolo Mattioli, Sara De Magistris, Erilda Kamberi, Maria Serafini, Giordano Riccioni, Yuri Rosati, and Francesca Marchesani
with advanced NSCLC in a real-life context, the efficacy of the treatment was independent of the age. Factors associated with lower survival were the presence of brain or liver metastases or previous treatment with a tyrosine kinase inhibitor (TKI) drug.
Rectal Cancer
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
. 119 Van Cutsem E Nordlinger B Adam R . Towards a pan-European consensus on the treatment of patients with colorectal liver metastases . Eur J Cancer 2006 ; 42 : 2212 – 2221 . 120 Yoo PS Lopez-Soler RI Longo WE Cha CH . Liver
Systemic Management of Colorectal Cancer
Wells A. Messersmith
metachronous metastases, primary resection is preferred, with consideration of local therapy or neoadjuvant chemotherapy. The EORTC 40983 trial compared surgery alone with FOLFOX before and after surgery in patients with resectable liver metastases from CRC
Colon Cancer
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
– 207 . 95 Kemeny N . Management of liver metastases from colorectal cancer . Oncology (Williston Park) 2006 ; 20 : 1161 – 1176 , 1179 ; discussion 1179–1180, 1185–1166 . 96 Muratore A Zorzi D Bouzari H . Asymptomatic
Colon Cancer, Version 3.2014
Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
retrospective study of 155 patients who underwent hepatic resection for colorectal liver metastases, patients with synchronous liver metastases had more sites of liver involvement ( P =.008) and more bilobar metastases ( P =.016) than patients diagnosed with
Colon Cancer
Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, and Christopher Willett
, with the liver the most common site of involvement. 144 However, 20% to 34% of patients with colorectal cancer present with synchronous liver metastases. 143 , 145 Some evidence indicates that synchronous metastatic colorectal liver disease is
Modification and Implementation of NCCN Guidelines™ on Colon Cancer in the Middle East and North Africa Region
Fikri İçli, Hakan Akbulut, Shouki Bazarbashi, Mehmet Ayhan Kuzu, Mohandas K. Mallath, Kakil Ibrahim Rasul, Scott Strong, Aamir Ali Syed, Faruk Zorlu, and Paul F. Engstrom
– 454 . 14. Dawood O Mahadevan A Goodman KA . Stereotactic body radiation therapy for liver metastases . Eur J Cancer 2009 ; 45 : 2947 – 2959 . 15. Fuss M Thomas CR Jr. Stereotactic body radiation therapy: an ablative
